A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients With Small Cell Lung Cancer (SCLC) or Advanced Solid Tumors.
Latest Information Update: 30 Aug 2021
Price :
$35 *
At a glance
- Drugs Palcitoclax (Primary)
- Indications Brain metastases; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 24 Aug 2021 Status changed from recruiting to discontinued.
- 11 Aug 2020 Planned End Date changed from 28 Dec 2019 to 1 Oct 2021.
- 11 Aug 2020 Planned primary completion date changed from 28 Dec 2019 to 1 Oct 2021.